X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/castle-creek-biosciences-announces-publication-of-preclinical-study-for-potential-in-vivo-gene-therapy-in-nature-communications-301614779.html
https://endpts.com/scoop-after-pulling-ipo-ambitions-last-december-jeff-aronins-castle-creek-turns-to-private-backers/
https://endpts.com/a-jeff-aronin-startup-quietly-yanks-its-ipo-as-the-biotech-market-ends-year-on-a-whimper/
https://www.prnewswire.com/news-releases/castle-creek-biosciences-awarded-fda-orphan-products-development-grant-to-support-defi-rdeb-a-pivotal-phase-3-study-of-fcx-007-investigational-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa-301405636.html
https://www.fiercebiotech.com/biotech/castle-creek-eliem-and-adagio-three-biotechs-filed-for-ipos-friday-continued-public-frenzy
https://www.prnewswire.com/news-releases/castle-creek-biosciences-announces-first-patient-dosed-in-defi-rdeb-phase-3-clinical-trial-of-debcoemagene-autoficel-d-fi-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa-301161536.html
https://pipelinereview.com/index.php/2020101676201/DNA-RNA-and-Cells/Castle-Creek-Biosciences-Announces-First-Patient-Dosed-in-Phase-1/2-Clinical-Trial-of-FCX-013-Gene-Therapy-for-Treatment-of-Moderate-to-Severe-Localized-Scleroderma.html
https://www.prnewswire.com/news-releases/castle-creek-biosciences-announces-first-patient-dosed-in-phase-12-clinical-trial-of-fcx-013-gene-therapy-for-treatment-of-moderate-to-severe-localized-scleroderma-301152980.html
https://www.castlecreekpharma.com/castle-creek-pharmaceutical-holdings-completes-acquisition-of-fibrocell-science/
https://www.biospace.com/article/releases/castle-creek-pharmaceutical-holdings-announces-agreement-to-acquire-fibrocell/?s=79
Market Place
Share 
